Endogenous nitric oxide synthase inhibitors in the biology of disease: Markers, mediators, and regulators?

Arteriosclerosis, Thrombosis, and Vascular Biology

Volumn 32, Issue 6, 2012, Pages 1343-1353

  Caplin, Ben ^a   Leiper, James ^b  

^a ROYAL FREE AND UNIVERSITY COLLEGE MEDICAL SCHOOL   (United Kingdom)

^b MRC CLINICAL SCIENCES CENTRE   (United Kingdom)

Author keywords

Asymmetric dimethylarginine; Kidney; Nitric oxide; Nitric oxide synthase; Vascular biology

Indexed keywords

6 N,N' DIMETHYLARGININE; ALANINE GLYOXYLATE AMINOTRANSFERASE; ARGININE; CITRULLINE; DIMETHYLAMINE; DIMETHYLARGININASE; HIGH DENSITY LIPOPROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; MITOCHONDRIAL ENZYME; N(G) METHYLARGININE; N(G),N(G) DIMETHYLARGININE; NITRIC OXIDE SYNTHASE; NITRIC OXIDE SYNTHASE INHIBITOR; REACTIVE OXYGEN METABOLITE; SMALL INTERFERING RNA; TOLAFENTRINE; TRIACYLGLYCEROL;

ALZHEIMER DISEASE; AMINO ACID BLOOD LEVEL; APOPTOSIS; BIOCHEMISTRY; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CELL ADHESION; CHOLESTEROL BLOOD LEVEL; CHRONIC KIDNEY DISEASE; CONNECTIVE TISSUE DISEASE; CONTROLLED CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; ELECTRON SPIN RESONANCE; ENDOTHELIUM CELL; ENZYME ACTIVE SITE; ENZYME INHIBITION; ENZYME METABOLISM; ENZYME POLYMORPHISM; ENZYME REGULATION; GENE EXPRESSION; GENETIC VARIABILITY; HEART INFARCTION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPERTENSION; HYPERTHYROIDISM; HYPOTHYROIDISM; KIDNEY FAILURE; KIDNEY FUNCTION; LIVER DISEASE; LIVER FUNCTION; MITOCHONDRION; NONHUMAN; PATHOGENESIS; PERIPHERAL VASCULAR DISEASE; PHYSIOLOGY; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PULMONARY HYPERTENSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; RISK FACTOR; SEPTIC SHOCK; SICKLE CELL ANEMIA; STROKE; SUPPLEMENTATION; UNSPECIFIED SIDE EFFECT; VASCULAR BIOLOGY; VIRAL GENE DELIVERY SYSTEM;

AMIDOHYDROLASES; ANIMALS; ARGININE; BINDING SITES; BINDING, COMPETITIVE; BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; CARDIOVASCULAR DISEASES; CATALYTIC DOMAIN; ENZYME INHIBITORS; HUMANS; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; OMEGA-N-METHYLARGININE;

EID: 84861531896     PISSN: 10795642     EISSN: 15244636     Source Type: Journal    
DOI: 10.1161/ATVBAHA.112.247726     Document Type: Review

References (131)

1. Kakimoto Y, Akazawa S. Isolation and identification of N-G,N-G-and N-G,N'-G-dimethyl-arginine, N-epsilon-mono-, di-, and trimethyllysine, and glucosylgalactosyl-and galactosyl-delta-hydroxylysine from human urine. J Biol Chem. 1970;245:5751-5758.
2. McBride AE, Silver PA. State of the arg: protein methylation at arginine comes of age. Cell. 2001;106:5-8.
3. MacAllister RJ, Whitley GS, Vallance P. Effects of guanidino and uremic compounds on nitric oxide pathways. Kidney Int. 1994;45:737-742.
4. Vallance P, Leone A, Calver A, et al. Accumulation of an endogenous inhibitor of nitric oxide synthesis in chronic renal failure. Lancet. 1992;339:572-575.
5. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature. 1987;327:524-526.
6. Brunner H, Cockcroft JR, Deanfield J, Donald A, Ferrannini E, Halcox J, Kiowski W, Luscher TF, Mancia G, Natali A, Oliver JJ, Pessina AC, Rizzoni D, Rossi GP, Salvetti A, Spieker LE, Taddei S, Webb DB; Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. Endothelial function and dysfunction. Part II: Association with cardiovascular risk factors and diseases. A statement by the Working Group on Endothelins and Endothelial Factors of the European Society of Hypertension. J Hypertens. 2005;23:233-246.
7. Mason RP, Cockcroft JR. Targeting nitric oxide with drug therapy. J Clin Hypertens (Greenwich) 2006;8(12 Suppl 4):40-52.
8. Münzel T, Daiber A, Gori T. Nitrate therapy: new aspects concerning molecular action and tolerance. Circulation. 2011;123:2132-2144.
9. López A, Lorente JA, Steingrub J, Bakker J, McLuckie A, Willatts S, Brockway M, Anzueto A, Holzapfel L, Breen D, Silverman MS, Takala J, Donaldson J, Arneson C, Grove G, Grossman S, Grover R. Multiplecenter, randomized, placebo-controlled, double-blind study of the nitric oxide synthase inhibitor 546C88: effect on survival in patients with septic shock. Crit Care Med. 2004;32:21-30.
10. Ghofrani HA, Osterloh IH, Grimminger F. Sildenafil: from angina to erectile dysfunction to pulmonary hypertension and beyond. Nat Rev Drug Discov. 2006;5:689-702.
11. Meyer J, Richter N, Hecker M. High-performance liquid chromatographic determination of nitric oxide synthase-related arginine derivatives in vitro and in vivo. Anal Biochem. 1997;247:11-16.
12. Tsikas D, Böger RH, Sandmann J, Bode-Boger SM, Frolich JC. Endogenous nitric oxide synthase inhibitors are responsible for the L-arginine paradox. FEBS Lett. 2000;478:1-3.
13. Teerlink T. HPLC analysis of ADMA and other methylated L-arginine analogs in biological fluids. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:21-29.
14. Aucella F, Maas R, Vigilante M, Tripipepi G, Schwedhelm E, Margaglione M, Gesualdo L, Boeger R, Zoccali C. Methylarginines and mortality in patients with end stage renal disease: a prospective cohort study. Atherosclerosis. 2009;207:541-545.
15. Kielstein JT, Salpeter SR, Bode-Boeger SM, Cooke JP, Fliser D. Symmetric dimethylarginine (SDMA) as endogenous marker of renal function-a meta-analysis. Nephrol Dial Transplant. 2006;21:2446-2451.
16. Tsikas D, Thum T, Becker T, Pham VV, Chobanyan K, Mitschke A, Beckmann B, Gutzki FM, Bauersachs J, Stichtenoth DO. Accurate quantification of dimethylamine (DMA) in human urine by gas chromatography-mass spectrometry as pentafluorobenzamide derivative: evaluation of the relationship between DMA and its precursor asymmetric dimethylarginine (ADMA) in health and disease. J Chromatogr B Analyt Technol Biomed Life Sci. 2007;851:229-239.
17. Achan V, Broadhead M, Malaki M, Whitley G, Leiper J, MacAllister R, Vallance P. Asymmetric dimethylarginine causes hypertension and cardiac dysfunction in humans and is actively metabolized by dimethylarginine dimethylaminohydrolase. Arterioscler Thromb Vasc Biol. 2003;23:1455-1459.
18. Ogawa T, Kimoto M, Watanabe H, Sasaoka K. Metabolism of NG,NG-and NG,N'G-dimethylarginine in rats. Arch Biochem Biophys. 1987;252:526-537.
19. Bulau P, Zakrzewicz D, Kitowska K, Leiper J, Gunther A, Grimminger F, Eickelberg O. Analysis of methylarginine metabolism in the cardiovascular system identifies the lung as a major source of ADMA. Am J Physiol Lung Cell Mol Physiol. 2007;292:L18-24.
20. Nijveldt RJ, Teerlink T, van Guldener C, Prins HA, van Lambalgen AA, Stehouwer CD, Rauwerda JA, van Leeuwen PA. Handling of asymmetrical dimethylarginine and symmetrical dimethylarginine by the rat kidney under basal conditions and during endotoxaemia. Nephrol Dial Transplant. 2003;18:2542-2550.
21. Nijveldt RJ, Van Leeuwen PA, Van Guldener C, Stehouwer CD, Rauwerda JA, Teerlink T. Net renal extraction of asymmetrical (ADMA) and symmetrical (SDMA) dimethylarginine in fasting humans. Nephrol Dial Transplant. 2002;17:1999-2002.
22. Bogle RG, MacAllister RJ, Whitley GS, Vallance P. Induction of NG-monomethyl-L-arginine uptake: a mechanism for differential inhibition of NO synthases? Am J Physiol. 1995;269(3 Pt 1):C750-C756.
23. Cardounel AJ, Cui H, Samouilov A, Johnson W, Kearns P, Tsai AL, Berka V, Zweier JL. Evidence for the pathophysiological role of endogenous methylarginines in regulation of endothelial NO production and vascular function. J Biol Chem. 2007;282:879-887.
24. Cardounel AJ, Xia Y, Zweier JL. Endogenous methylarginines modulate superoxide as well as nitric oxide generation from neuronal nitric-oxide synthase: differences in the effects of monomethyl-and dimethylarginines in the presence and absence of tetrahydrobiopterin. J Biol Chem. 2005;280:7540-7549.
25. Druhan LJ, Forbes SP, Pope AJ, Chen CA, Zweier JL, Cardounel AJ. Regulation of eNOS-derived superoxide by endogenous methylarginines. Biochemistry. 2008;47:7256-7263.
26. Jiang DJ, Jia SJ, Dai Z, Li YJ. Asymmetric dimethylarginine induces apoptosis via p38 MAPK/caspase-3-dependent signaling pathway in endothelial cells. J Mol Cell Cardiol. 2006;40:529-539.
27. Smith CL, Anthony S, Hubank M, Leiper JM, Vallance P. Effects of ADMA upon gene expression: an insight into the pathophysiological significance of raised plasma ADMA. PLoS Med. 2005;2:e264.
28. Böger RH, Bode-Böger SM, Tsao PS, Lin PS, Chan JR, Cooke JP. An endogenous inhibitor of nitric oxide synthase regulates endothelial adhesiveness for monocytes. J Am Coll Cardiol. 2000;36:2287-2295.
29. Chan JR, Böger RH, Bode-Böger SM, Tangphao O, Tsao PS, Blaschke TF, Cooke JP. Asymmetric dimethylarginine increases mononuclear cell adhesiveness in hypercholesterolemic humans. Arterioscler Thromb Vasc Biol. 2000;20:1040-1046.
30. Wojciak-Stothard B, Torondel B, Tsang LY, Fleming I, Fisslthaler B, Leiper JM, Vallance P. The ADMA/DDAH pathway is a critical regulator of endothelial cell motility. J Cell Sci. 2007;120(Pt 6):929-942.
31. Fiedler LR, Bachetti T, Leiper J, Zachary I, Chen L, Renne T, Wojciak-Stothard B. The ADMA/DDAH pathway regulates VEGF-mediated angiogenesis. Arterioscler Thromb Vasc Biol. 2009;29:2117-2124.
32. Ueda S, Kato S, Matsuoka H, Kimoto M, Okuda S, Morimatsu M, Imaizume I. Regulation of cytokine-induced nitric oxide synthesis by asymmetric dimethylarginine: role of dimethylarginine dimethylaminohydrolase. Circ Res. 2003;92:226-233.
33. Kielstein JT, Impraim B, Simmel S, Bode-Boger SM, Tsikas D, Frolich JC, Hoeper MM, Haller H, Fliser D. Cardiovascular effects of systemic nitric oxide synthase inhibition with asymmetrical dimethylarginine in humans. Circulation. 2004;109:172-177.
34. Suda O, Tsutsui M, Morishita T, Tasaki H, Ueno S, Nakata S, Tsujimoto T, Toyohira Y, Hayashida Y, Sasaguri Y, Ueta Y, Nakashima Y, Yanagihara N. Asymmetric dimethylarginine produces vascular lesions in endothelial nitric oxide synthase-deficient mice: involvement of reninangiotensin system and oxidative stress. Arterioscler Thromb Vasc Biol. 2004;24:1682-1688.
35. Creager MA, Gallagher SJ, Girerd XJ, Coleman SM, Dzau VJ, Cooke JP. L-arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest. 1992;90:1248-1253.
36. Bode-Böger SM, Böger RH, Alfke H, Heinzel D, Tsikas D, Creutzig A, Alexander K, Frolich JC. L-arginine induces nitric oxide-dependent vasodilation in patients with critical limb ischemia. A randomized, controlled study. Circulation. 1996;93:85-90.
37. Wilson AM, Harada R, Nair N, Balasubramanian N, Cooke JP. L-arginine supplementation in peripheral arterial disease: no benefit and possible harm. Circulation. 2007;116:188-195.
38. Closs EI, Basha FZ, Habermeier A, Forstermann U. Interference of L-arginine analogues with L-arginine transport mediated by the y+ carrier hCAT-2B. Nitric Oxide 1997;1:65-73.
39. Tojo A, Welch WJ, Bremer V, Kimoto M, Kimura K, Omata M, Ogawa T, Vallance P, Wilcox OS. Colocalization of demethylating enzymes and NOS and functional effects of methylarginines in rat kidney. Kidney Int. 1997;52:1593-1601.
40. Schepers E, Glorieux G, Dou L, et al.; European Uremic Toxin Work Group (EUTox). Guanidino compounds as cause of cardiovascular damage in chronic kidney disease: an in vitro evaluation. Blood Purif. 2010;30:277-287.
41. Ogawa T, Kimoto M, Sasaoka K. Occurrence of a new enzyme catalyzing the direct conversion of NG,NG-dimethyl-L-arginine to L-citrulline in rats. Biochem Biophys Res Commun. 1987;148:671-677.
42. Bedford MT, Richard S. Arginine methylation an emerging regulator of protein function. Mol Cell. 2005;18:263-272.
43. Smith WA, Schurter BT, Wong-Staal F, et al. Arginine methylation of RNA helicase a determines its subcellular localization. J Biol Chem. 2004;279:22795-22798.
44. Pal S, Vishwanath SN, Erdjument-Bromage H, et al. Human SWI/SNFassociated PRMT5 methylates histone H3 arginine 8 and negatively regulates expression of ST7 and NM23 tumor suppressor genes. Mol Cell Biol. 2004;24:9630-9645.
45. Shirakawa T, Kako K, Shimada T, et al. Production of free methylarginines via the proteasome and autophagy pathways in cultured cells. Mol Med Report. 2011;4:615-620.
46. Carello KA, Whitesall SE, Lloyd MC, et al. Asymmetrical dimethylarginine plasma clearance persists after acute total nephrectomy in rats. Am J Physiol Heart Circ Physiol. 2006;290:H209-H216.
47. Wang Y, Wysocka J, Sayegh J, et al. Human PAD4 regulates histone arginine methylation levels via demethylimination. Science. 2004;306:279-283.
48. Ogawa T, Kimoto M, Sasaoka K. Purification and properties of a new enzyme, NG,NG-dimethylarginine dimethylaminohydrolase, from rat kidney. J Biol Chem. 1989;264:10205-10209.
49. Leiper JM, Santa Maria J, Chubb A, et al. Identification of two human dimethylarginine dimethylaminohydrolases with distinct tissue distributions and homology with microbial arginine deiminases. Biochem J. 1999;343 Pt 1:209-214.
50. Tran CT, Fox MF, Vallance P, et al. Chromosomal localization, gene structure, and expression pattern of DDAH1: comparison with DDAH2 and implications for evolutionary origins. Genomics. 2000;68:101-105.
51. Forbes SP, Druhan LJ, Guzman JE, et al. Mechanism of 4-HNE mediated inhibition of hDDAH-1: implications in no regulation. Biochemistry. 2008;47:1819-1826.
52. Murray-Rust J, Leiper J, McAlister M, et al. Structural insights into the hydrolysis of cellular nitric oxide synthase inhibitors by dimethylarginine dimethylaminohydrolase. Nat Struct Biol. 2001;8:679-683.
53. Wang D, Gill PS, Chabrashvili T, et al. Isoform-specific regulation by N(G),N(G)-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and vascular endothelium-derived relaxing factor/NO. Circ Res. 2007;101:627-635.
54. Onozato ML, Tojo A, Leiper J, et al. Expression of NG,NGdimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes. 2008;57:172-180.
55. Matsuguma K, Ueda S, Yamagishi S, et al. Molecular mechanism for elevation of asymmetric dimethylarginine and its role for hypertension in chronic kidney disease. J Am Soc Nephrol. 2006;17:2176-2183.
56. Leiper J, Nandi M, Torondel B, et al. Disruption of methylarginine metabolism impairs vascular homeostasis. Nat Med 2007;13:198-203.
57. Dayoub H, Achan V, Adimoolam S, et al. Dimethylarginine dimethylaminohydrolase regulates nitric oxide synthesis: genetic and physiological evidence. Circulation. 2003;108:3042-3047.
58. Hasegawa K, Wakino S, Tatematsu S, et al. Role of asymmetric dimethylarginine in vascular injury in transgenic mice overexpressing dimethylarginie dimethylaminohydrolase 2. Circ Res. 2007;101:e2-e10.
59. Wang D, Gill PS, Chabrashvili T, et al. Isoform-specific regulation by NG,NG-dimethylarginine dimethylaminohydrolase of rat serum asymmetric dimethylarginine and Vascular Endothelium-Derived Relaxing Factor/NO. Circ Res. 2007;101:627-635.
60. Hu X, Atzler D, Xu X, et al. Dimethylarginine dimethylaminohydrolase-1 is the critical enzyme for degrading the cardiovascular risk factor asymmetrical dimethylarginine. Arterioscler Thromb Vasc Biol. 2011;31:1540-1546.
61. Hu X, Xu X, Zhu G, et al. Vascular endothelial-specific dimethylarginine dimethylaminohydrolase-1-deficient mice reveal that vascular endothelium plays an important role in removing asymmetric dimethylarginine. Circulation. 2009;120:2222-2229.
62. Breckenridge RA, Kelly P, Nandi M, et al. A role for Dimethylarginine Dimethylaminohydrolase 1 (DDAH1) in mammalian development. Int J Dev Biol. 2010;54:215-220.
63. Arcrigoni FI, Vallance P, Haworth SG, et al. Metabolism of asymmetric dimethylarginines is regulated in the lung developmentally and with pulmonary hypertension induced by hypobaric hypoxia. Circulation 2003;107:1195-201.
64. Onozato ML, Tojo A, Leiper J, et al. Expression of NG,NGdimethylarginine dimethylaminohydrolase and protein arginine N-methyltransferase isoforms in diabetic rat kidney: effects of angiotensin II receptor blockers. Diabetes. 2008;57:172-180.
65. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation, 2004;109:III27-III32.
66. Jacobi J, Maas R, Cardounel AJ, et al. Dimethylarginine dimethylaminohydrolase overexpression ameliorates atherosclerosis in apolipoprotein E-deficient mice by lowering asymmetric dimethylarginine. Am J Pathol. 2010;176:2559-2570.
67. Pullamsetti SS, Savai R, Dumitrascu R, et al. The role of dimethylarginine dimethylaminohydrolase in idiopathic pulmonary fibrosis. Sci Transl Med. 2011;3:87ra53.
68. Caplin B, Nitsch D, Gill H, et al. Circulating methylarginine levels and the decline in renal function in patients with chronic kidney disease are modulated by DDAH1 polymorphisms. Kidney Int. 2010;77:459-467.
69. Abhary S, Burdon KP, Kuot A, et al. Sequence variation in DDAH1 and DDAH2 genes is strongly and additively associated with serum ADMA concentrations in individuals with type 2 diabetes. PLoS ONE. 2010;5:e9462.
70. Ding H, Wu B, Wang H, et al. A novel loss-of-function DDAH1 promoter polymorphism is associated with increased susceptibility to thrombosis stroke and coronary heart disease. Circ Res. 2010;106:1145-1152.
71. Jones LC, Tran CT, Leiper JM, et al. Common genetic variation in a basal promoter element alters DDAH2 expression in endothelial cells. Biochem Biophys Res Commun. 2003;310:836-843.
72. Humphries SE, Drenos F, Ken-Dror G, et al. Coronary heart disease risk prediction in the era of genome-wide association studies: current status and what the future holds. Circulation. 2010;121:2235-2248.
73. Lanktree MB, Dichgans M, Hegele RA. Advances in genomic analysis of stroke: what have we learned and where are we headed? Stroke. 2010;41:825-832.
74. Chambers JC, Zhang W, Lord GM, et al. Genetic loci influencing kidney function and chronic kidney disease. Nat Genet. 2010;42:373-375.
75. Valkonen VP, Tuomainen TP, Laaksonen R. DDAH gene and cardiovascular risk. Vasc Med. 2005;10 Suppl 1:S45-S48.
76. Palm F, Onozato ML, Luo Z, et al. Dimethylarginine dimethylaminohydrolase (DDAH): expression, regulation, and function in the cardiovascular and renal systems. Am J Physiol Heart Circ Physiol. 2007;293:H3227-H3245.
77. Hu T, Chouinard M, Cox AL, et al. Farnesoid X receptor agonist reduces serum asymmetric dimethylarginine levels through hepatic dimethylarginine dimethylaminohydrolase-1 gene regulation. J Biol Chem. 2006;281:39831-39838.
78. Achan V, Tran CT, Arrigoni F, et al. all-trans-Retinoic acid increases nitric oxide synthesis by endothelial cells: a role for the induction of dimethylarginine dimethylaminohydrolase. Circ Res. 2002;90:764-769.
79. Leiper J, Murray-Rust J, McDonald N, et al. S-nitrosylation of dimethylarginine dimethylaminohydrolase regulates enzyme activity: further interactions between nitric oxide synthase and dimethylarginine dimethylaminohydrolase. Proc Natl Acad Sci USA. 2002;99:13527-13532.
80. Knipp M, Braun O, Gehrig PM, et al. Zn(II)-free dimethylargininase-1 (DDAH-1) is inhibited upon specific Cys-S-nitrosylation. J Biol Chem. 2003;278:3410-3416.
81. Tain YL, Baylis C. Determination of dimethylarginine dimethylaminohydrolase activity in the kidney. Kidney Int. 2007;72:886-889.
82. Sakurada M, Shichiri M, Imamura M, et al. Nitric oxide upregulates dimethylarginine dimethylaminohydrolase-2 via cyclic GMP induction in endothelial cells. Hypertension. 2008;52:903-909.
83. Stühlinger MC, Tsao PS, Her JH, et al. Homocysteine impairs the nitric oxide synthase pathway: role of asymmetric dimethylarginine. Circulation. 2001;104:2569-2575.
84. Pullamsetti SS, Savai R, Schaefer MB, et al. cAMP phosphodiesterase inhibitors increases nitric oxide production by modulating dimethylarginine dimethylaminohydrolases. Circulation. 2011;123:1194-1204.
85. Kostourou V, Robinson SP, Cartwright JE, et al. Dimethylarginine dimethylaminohydrolase I enhances tumour growth and angiogenesis. Br J Cancer. 2002;87:673-680.
86. Boult JK, Walker-Samuel S, Jamin Y, et al. Active site mutant dimethylarginine dimethylaminohydrolase 1 expression confers an intermediate tumour phenotype in C6 gliomas. J Pathol. 2011;225:344-352.
87. Ogawa T, Kimoto M, Sasaoka K. Dimethylarginine:pyruvate aminotransferase in rats. Purification, properties, and identity with alanine:glyoxylate aminotransferase 2. J Biol Chem. 1990;265:20938-20945.
88. Lee IS, Nishikimi M, Inoue M, et al. Specific expression of alanine-glyoxylate aminotransferase 2 in the epithelial cells of Henle's loop. Nephron. 1999;83:184-185.
89. Rodionov RN, Murry DJ, Vaulman SF, et al. Human alanine-glyoxylate aminotransferase 2 lowers asymmetric dimethylarginine and protects from inhibition of nitric oxide production. J Biol Chem. 2010;285:5385-5391.
90. Poderoso JJ. The formation of peroxynitrite in the applied physiology of mitochondrial nitric oxide. Arch Biochem Biophys. 2009;484:214-220.
91. Venkatakrishnan P, Nakayasu ES, Almeida IC, et al. Absence of nitricoxide synthase in sequentially purified rat liver mitochondria. J Biol Chem. 2009;284:19843-19855.
92. Böger RH, Bode-Böger SM, Thiele W, et al. Biochemical evidence for impaired nitric oxide synthesis in patients with peripheral arterial occlusive disease. Circulation. 1997;95:2068-2074.
93. Pullamsetti S, Kiss L, Ghofrani HA, et al. Increased levels and reduced catabolism of asymmetric and symmetric dimethylarginines in pulmonary hypertension. FASEB J. 2005;19:1175-1177.
94. O'Dwyer MJ, Dempsey F, Crowley V, et al. Septic shock is correlated with asymmetrical dimethyl arginine levels, which may be influenced by a polymorphism in the dimethylarginine dimethylaminohydrolase II gene: a prospective observational study. Crit Care. 2006;10:R139.
95. Schulze F, Lenzen H, Hanefeld C, et al. Asymmetric dimethylarginine is an independent risk factor for coronary heart disease: results from the multicenter Coronary Artery Risk Determination investigating the Influence of ADMA Concentration (CARDIAC) study. Am Heart J. 2006;152:493.e1-493.e8.
96. Eid HM, Eritsland J, Larsen J, et al. Increased levels of asymmetric dimethylarginine in populations at risk for atherosclerotic disease. Effects of pravastatin. Atherosclerosis. 2003;166:279-284.
97. Altinova AE, Arslan M, Sepici-Dincel A, et al. Uncomplicated type 1 diabetes is associated with increased asymmetric dimethylarginine concentrations. J Clin Endocrinol Metab. 2007;92:1881-1885.
98. Sugai M, Ohta A, Ogata Y, et al. Asymmetric dimethylarginine (ADMA) in the aqueous humor of diabetic patients. Endocr J. 2007;54:303-309.
99. Pettersson A, Hedner T, Milsom I. Increased circulating concentrations of asymmetric dimethyl arginine (ADMA), an endogenous inhibitor of nitric oxide synthesis, in preeclampsia. Acta Obstet Gynecol Scand. 1998;77:808-813.
100. Selley ML. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging. 2003;24:903-907.
101. Dooley A, Gao B, Bradley N, et al. Abnormal nitric oxide metabolism in systemic sclerosis: increased levels of nitrated proteins and asymmetric dimethylarginine. Rheumatology (Oxford). 2006;45:676-684.
102. Mookerjee RP, Malaki M, Davies NA, et al. Increasing dimethylarginine levels are associated with adverse clinical outcome in severe alcoholic hepatitis. Hepatology. 2007;45:62-71.
103. Hermenegildo C, Medina P, PeiróM, et al. Plasma concentration of asymmetric dimethylarginine, an endogenous inhibitor of nitric oxide synthase, is elevated in hyperthyroid patients. J Clin Endocrinol Metab. 2002;87:5636-5640.
104. Ozcan O, Cakir E, Yaman H, et al. The effects of thyroxine replacement on the levels of serum asymmetric dimethylarginine (ADMA) and other biochemical cardiovascular risk markers in patients with subclinical hypothyroidism. Clin Endocrinol (Oxf). 2005;63:203-206.
105. Yoo JH, Lee SC. Elevated levels of plasma homocyst(e)ine and asymmetric dimethylarginine in elderly patients with stroke. Atherosclerosis. 2001;158:425-430.
106. Schnog JB, Teerlink T, van der Dijs FP, et al.; CURAMA Study Group. Plasma levels of asymmetric dimethylarginine (ADMA), an endogenous nitric oxide synthase inhibitor, are elevated in sickle cell disease. Ann Hematol. 2005;84:282-286.
107. Selley ML. Increased concentrations of homocysteine and asymmetric dimethylarginine and decreased concentrations of nitric oxide in the plasma of patients with Alzheimer's disease. Neurobiol Aging. 2003:24:903-907.
108. Arlt S, Schulze F, Eichenlaub M, et al. Asymmetrical dimethylarginine is increased in plasma and decreased in cerebrospinal fluid of patients with Alzheimer's disease. Dement Geriatr Cogn Disord. 2008;26:58-64.
109. Huemer M, Simma B, Mayr D, et al. Low levels of asymmetric dimethylarginine in children with diabetes mellitus type I compared with healthy children. J Pediatr. 2011;158:602-606.e1.
110. Sibal L, Agarwal SC, Schwedhelm E, et al. A study of endothelial function and circulating asymmetric dimethylarginine levels in people with Type 1 diabetes without macrovascular disease or microalbuminuria. Cardiovasc Diabetol. 2009;8:27.
111. Abe T, Tohgi H, Murata T, et al. Reduction in asymmetrical dimethylarginine, an endogenous nitric oxide synthase inhibitor, in the cerebrospinal fluid during aging and in patients with Alzheimer's disease. Neurosci Lett. 2001;312:177-179.
112. Böger RH, Sullivan LM, Schwedhelm E, et al. Plasma asymmetric dimethylarginine and incidence of cardiovascular disease and death in the community. Circulation. 2009;119:1592-1600.
113. Leong T, Zylberstein D, Graham I, et al.; Swedish-Irish-Norwegian Collaboration. Asymmetric dimethylarginine independently predicts fatal and nonfatal myocardial infarction and stroke in women: 24-year follow-up of the population study of women in Gothenburg. Arterioscler Thromb Vasc Biol. 2008;28:961-967.
114. Valkonen VP, PäiväH, Salonen JT, et al. Risk of acute coronary events and serum concentration of asymmetrical dimethylarginine. Lancet. 2001;358:2127-21288.
115. Maas R, Schulze F, Baumert J, et al. Asymmetric dimethylarginine, smoking, and risk of coronary heart disease in apparently healthy men: prospective analysis from the population-based Monitoring of Trends and Determinants in Cardiovascular Disease/Kooperative Gesundheitsforschung in der Region Augsburg study and experimental data. Clin Chem. 2007;53:693-701.
116. Cavusoglu E, Ruwende C, Chopra V, et al. Relationship of baseline plasma ADMA levels to cardiovascular outcomes at 2 years in men with acute coronary syndrome referred for coronary angiography. Coron Artery Dis. 2009;20:112-117.
117. Schnabel R, Blankenberg S, Lubos E, et al. Asymmetric dimethylarginine and the risk of cardiovascular events and death in patients with coronary artery disease: results from the AtheroGene Study. Circ Res. 2005;97:e53-e59.
118. Lu TM, Ding YA, Lin SJ, et al. Plasma levels of asymmetrical dimethylarginine and adverse cardiovascular events after percutaneous coronary intervention. Eur Heart J. 2003;24:1912-1919.
119. Cavusoglu E, Ruwende C, Chopra V, et al. Relation of baseline plasma ADMA levels to cardiovascular morbidity and mortality at two years in men with diabetes mellitus referred for coronary angiography. Atherosclerosis. 2010;210:226-231.
120. Krzyzanowska K, Mittermayer F, Wolzt M, et al. Asymmetric dimethylarginine predicts cardiovascular events in patients with type 2 diabetes. Diabetes Care. 2007;30:1834-1839.
121. Lajer M, Tarnow L, Jorsal A, et al. Plasma concentration of asymmetric dimethylarginine (ADMA) predicts cardiovascular morbidity and mortality in type 1 diabetic patients with diabetic nephropathy. Diabetes Care. 2008;31:747-752.
122. Mittermayer F, Krzyzanowska K, Exner M, et al. Asymmetric dimethylarginine predicts major adverse cardiovascular events in patients with advanced peripheral artery disease. Arterioscler Thromb Vasc Biol 2006;26:2536-40.
123. Wilson AM, Shin DS, Weatherby C, et al. Asymmetric dimethylarginine correlates with measures of disease severity, major adverse cardiovascular events and all-cause mortality in patients with peripheral arterial disease. Vasc Med. 2010;15:267-274.
124. Ravani P, Tripepi G, Malberti F, et al. Asymmetrical dimethylarginine predicts progression to dialysis and death in patients with chronic kidney disease: a competing risks modeling approach. J Am Soc Nephrol. 2005;16:2449-2455.
125. Fliser D, Kronenberg F, Kielstein JT, et al. Asymmetric dimethylarginine and progression of chronic kidney disease: the mild to moderate kidney disease study. J Am Soc Nephrol. 2005;16:2456-2461.
126. Young JM, Terrin N, Wang X, et al. Asymmetric dimethylarginine and mortality in stages 3 to 4 chronic kidney disease. Clin J Am Soc Nephrol. 2009;4:1115-1120.
127. Kielstein JT, Bode-Böger SM, Hesse G, et al. Asymmetrical dimethylarginine in idiopathic pulmonary arterial hypertension. Arterioscler Thromb Vasc Biol. 2005;25:1414-1418.
128. Miyazaki H, Matsuoka H, Cooke JP, et al. Endogenous nitric oxide synthase inhibitor: a novel marker of atherosclerosis. Circulation. 1999;99:1141-1146.
129. Kielstein JT, Bode-Böger SM, Frölich JC, et al. Asymmetric dimethylarginine, blood pressure, and renal perfusion in elderly subjects. Circulation. 2003;107:1891-1895.
130. Juonala M, Viikari JS, Alfthan G, et al. Brachial artery flow-mediated dilation and asymmetrical dimethylarginine in the cardiovascular risk in young Finns study. Circulation. 2007;116:1367-1373.
131. Böger RH, Bode-Böger SM, Szuba A,. Asymmetric dimethylarginine (ADMA): a novel risk factor for endothelial dysfunction: its role in hypercholesterolemia. Circulation. 1998;98:1842-1847.